Cytosorbents (CTSO) Share-based Compensation Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.98% |
| Dec 31, 2025 | -18.86% |
| Sep 30, 2025 | -14.82% |
| Jun 30, 2025 | -11.40% |
| Mar 31, 2025 | 2.32% |
| Dec 31, 2024 | 13.38% |
| Sep 30, 2024 | 2.13% |
| Jun 30, 2024 | 46.81% |
| Mar 31, 2024 | 33.34% |
| Dec 31, 2023 | 1.18% |
| Sep 30, 2023 | 31.71% |
| Jun 30, 2023 | -22.71% |
| Mar 31, 2023 | 30.75% |
| Dec 31, 2022 | -9.88% |
| Sep 30, 2022 | 0.92% |
| Jun 30, 2022 | -0.96% |
| Mar 31, 2022 | 53.54% |
| Dec 31, 2021 | 36.41% |
| Sep 30, 2021 | 51.72% |
| Jun 30, 2021 | 25.89% |
| Mar 31, 2021 | 70.83% |
| Dec 31, 2020 | 83.20% |
| Sep 30, 2020 | 57.07% |
| Jun 30, 2020 | 66.05% |
| Mar 31, 2020 | 62.90% |
| Sep 30, 2019 | 60.53% |
| Jun 30, 2019 | 25.01% |
| Mar 31, 2019 | 31.74% |
| Dec 31, 2018 | 32.08% |
| Sep 30, 2018 | 27.45% |
| Jun 30, 2018 | 119.45% |
| Mar 31, 2018 | -0.78% |
| Dec 31, 2017 | 99.61% |
| Sep 30, 2017 | 138.53% |
| Jun 30, 2017 | 188.45% |
| Mar 31, 2017 | 180.44% |
| Dec 31, 2016 | -23.03% |
| Sep 30, 2016 | -17.75% |
| Jun 30, 2016 | 202.16% |
| Mar 31, 2016 | -9.47% |
| Dec 31, 2015 | 24.54% |
| Sep 30, 2015 | 41.66% |